Clinical Trials Logo

Brain Metastases, Adult clinical trials

View clinical trials related to Brain Metastases, Adult.

Filter by:

NCT ID: NCT05689619 Recruiting - Breast Cancer Clinical Trials

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

SILMET
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

NCT ID: NCT05559853 Recruiting - Brain Metastases Clinical Trials

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Start date: September 22, 2022
Phase:
Study type: Observational

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

NCT ID: NCT05545007 Recruiting - Clinical trials for Brain Metastases, Adult

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

SUPPORT
Start date: January 31, 2023
Phase: N/A
Study type: Interventional

This is a phase III randomized trial with the aim to compare preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.

NCT ID: NCT05480644 Recruiting - Clinical trials for Brain Metastases, Adult

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.

NCT ID: NCT05428852 Recruiting - Clinical trials for Brain Metastases, Adult

Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

This pilot study will be a single center, randomized controlled study of 24 participants with diagnosed BM (various primary disease sites) comparing the effect of a ketogenic (n=12) and AICR (n=12) diet. Potential participants will be identified via medical record reviews and chart reviews. Eligibility of patients will be assessed via medical record review. Randomization will be balanced by blocks of random sizes but no stratification due to the small sample size. Both groups will undergo a 16-week diet intervention where research dietitians will provide educations, recipes and grocery lists on the participants assigned diet. Each group will receive 4-7 days worth of food prior to testing days to both aid in transitioning to each dietary arm and to ensure that the metabolic needs for each arm are met. In an effort to maintain a patient centric focus and monitor changes in quality of life (QOL) all patients will complete psychosocial and behavioral inventories. These inventories aim to capture a holistic view on the proposed nutritional intervention during treatment. Primary outcomes will be determined at baseline, 8 weeks, and 16 weeks while patient-centric outcomes will be assessed every four weeks. Participants will have counseling by the attending physician for additional applicable medications for any treatment related side effects or toxicities. The intervention groups will undergo their randomized dietary regimen for 16 weeks.

NCT ID: NCT05419076 Recruiting - Lung Cancer Clinical Trials

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Start date: June 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

NCT ID: NCT05341739 Recruiting - Clinical trials for Brain Metastases, Adult

A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

Start date: December 14, 2021
Phase: N/A
Study type: Interventional

This is a research study to determine if performing stereotactic radiosurgery (SRS) prior to surgical resection of the brain metastasis (tumor) will improve local control, in other words, increase the possibility of total removal of the primary tumor without local recurrence on longterm follow up. This research study will also determine if pre-operative SRS will lower the risk of radionecrosis that is the breakdown of body tissue at the original tumor site, and the development of leptomeningeal disease.

NCT ID: NCT05267158 Recruiting - Clinical trials for Brain Metastases, Adult

The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA)

COIMBRA
Start date: April 26, 2019
Phase:
Study type: Observational [Patient Registry]

The incidence of brain metastases is expected to increase because of better treatments of primary tumours. Novel diagnostic and therapeutic techniques are continuously being developed, all of which need thorough evaluation before they can be implemented in clinical routine. Randomized Controlled Trials are the gold standard to do so, but they have shown many challenges, especially when applied in a cancer setting. .The 'cohort multiple Randomized Controlled Trial (cmRCT)' design is a promising design for multiple (simultaneous) randomized evaluations of experimental interventions, with potential for increased recruitment, comparability and long-term outcomes as a standard. This design will speed up the process of translating treatment innovations to the daily clinic.

NCT ID: NCT05144867 Recruiting - Breast Cancer Clinical Trials

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis

SRSvsWBRT
Start date: August 31, 2021
Phase: Phase 3
Study type: Interventional

This trial aims to assess the impact of SRS on overall survival, PFS, radiation toxicity and quality of life as compared to WBRT in oligometastatic brain disease in breast cancer patients. Total 98 patients with breast cancer with brain oligo-metastases will be included. The WBRT dosage schedule will be 30 Gy in 10 fractions over 2 weeks. For tumors with 2cm, SRS dose of 22 to 25 Gy will be delivered and tumor larger than 2 cm will be treated with doses of 18 to 20 Gy.

NCT ID: NCT05126875 Recruiting - Cancer Clinical Trials

Re-TREAT: Re-irradiation for Relapsed Brain Metastases

RE-TREAT
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The Re-TREAT study is a prospective clinical, phase 2, interventional, single-arm, multicenter trial for patients with local relapse of one or more brain metastases. Patients with recurrence of one or more brain metastases that have previously been treated with stereotactic radiosurgey (SRS) are treated with repeated SRS. The aim is to evaluate the efficacy and toxicity of salvage SRS. The primary outcome is local control of the relapsed tumor and the secondary endpoints include toxicity as evaluated by the investigator and quality of life measured as a patient reported outcome. As an exploratory endpoint, the value of advanced MRI (magnetic resonance imaging) and PET (positron emission tomography) imaging as a biomarker for prediction of response to treatment or toxicity will be studied.